The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Based on data from 173,960 and 385,505 patients without with ATG induction, respectively. ATG induction is the new5GC bearing rabbit anti-T cell IgG, we found no evidence that exposure to higher levels of anti-new5GC is associated with a higher incidence of colon cancer.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
there is no associated incidence of higher rates of colon cancer and there were 38 000 people that received this atg induction with the kidney transplant so there is really not good evidence in humans
this study is titled no increase in colon cancer risk following induction with new 5gc bearing rabbit anti-t cell igg in recipients of kidney transplants and they say in the conclusions or at the bottom of the abstract based on data from 173 960 and 385 505 patients without and with atg induction respectively atg induction is the new 5gc bearing rabbit anti-t cell igg we found no evidence that exposure to higher levels of anti-neu5gc is associated with a higher incidence of colon cancer
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.